Display options
Share it on

FEBS Open Bio. 2016 Jan 18;6(1):64-76. doi: 10.1002/2211-5463.12024. eCollection 2016 Jan.

Intestinal removal of free fatty acids from hosts by Lactobacilli for the treatment of obesity.

FEBS open bio

Hea-Jong Chung, Jae G Yu, In-Ah Lee, Ming-Jie Liu, Yan-Fei Shen, Satya P Sharma, Mohammad A H M Jamal, Jun-Hyun Yoo, Hyeon-Jin Kim, Seong-Tshool Hong

Affiliations

  1. Department of Biomedical Sciences and Institute for Medical Science Chonbuk National University Medical School Jeonju Chonbuk Korea.
  2. JINIS BDRD institute JINIS Biopharmaceuticals Co. Wanju Chonbuk Korea.
  3. Department of Family Medicine Samsung Medical Center Sungkyunkwan University School of Medicine Seoul Korea.

PMID: 27047743 PMCID: PMC4794792 DOI: 10.1002/2211-5463.12024

Abstract

Recent findings on the association of gut microbiota with various diseases, including obesity, prompted us to investigate the possibility of using a certain type of gut bacteria as a safe therapeutic for obesity. Lactobacillus mutants with enhanced capacity in absorption of free fatty acids (FFAs) were isolated to show reduced absorption of FFAs by the administered host, attributing to inhibition of body weight gain and body fat accumulation as well as amelioration of blood profiles. Consequently, high throughput screening of natural FFAs-absorbing intestinal microbes led to the isolation of Lactobacillus reuteri JBD30 l. The administration of Lactobacillus JBD30l lowered the concentration of FFAs in the gut fluid content of small intestine, thus reducing intestinal absorption of FFAs whereas promoting fecal excretion of FFAs. Animal data also confirmed that the efficacy of Lactobacillus JBD30l on body weight similar to that of orlistat, an FDA-approved pharmaceutical for long-term use to treat obesity. In a subsequent random, double-blind, placebo-controlled clinical trial (KCT0000452 at Clinical Research Information Service of Korea), there was a statistically significant difference in the percentage change in body weight between the Lactobacillus JBD301 and the placebo group (P = 0.026) as well as in the BMI (P = 0.036) from the 0-week assessment to the 12-week assessment. Our results show that FFA-absorbing Lactobacillus JBD301 effectively reduces dietary fat absorption, providing an ideal treatment for obesity with inherent safety.

Keywords: Lactobacillus; absorption; free fatty acid; intestinal; obesity

References

  1. JAMA. 1999 Jan 20;281(3):235-42 - PubMed
  2. Diabetes Metab J. 2012 Feb;36(1):13-25 - PubMed
  3. Annu Rev Public Health. 2001;22:355-75 - PubMed
  4. Cell Host Microbe. 2008 Apr 17;3(4):213-23 - PubMed
  5. Am J Clin Nutr. 1999 Jun;69(6):1108-16 - PubMed
  6. Eur J Clin Nutr. 2010 Jun;64(6):636-43 - PubMed
  7. Nature. 2012 Oct 4;490(7418):55-60 - PubMed
  8. Curr Opin Cardiol. 2006 Sep;21(5):479-85 - PubMed
  9. Diabetes Metab J. 2015 Aug;39(4):291-303 - PubMed
  10. JAMA. 2014 Jan 1;311(1):74-86 - PubMed
  11. Clin Pharmacol Ther. 2011 Jul;90(1):40-51 - PubMed
  12. Food Microbiol. 2006 Feb;23(1):74-81 - PubMed
  13. J Clin Invest. 2011 Jun;121(6):2126-32 - PubMed
  14. Int J Obes. 1991 Mar;15(3):205-11 - PubMed
  15. Science. 2013 Sep 6;341(6150):1241214 - PubMed
  16. Nature. 2006 Dec 21;444(7122):1027-31 - PubMed
  17. Am J Physiol. 1992 Nov;263(5 Pt 1):E913-9 - PubMed
  18. Genome Biol Evol. 2014 Mar;6(3):482-8 - PubMed
  19. J Chronic Dis. 1987;40(9):911-2 - PubMed
  20. N Engl J Med. 2010 Sep 2;363(10):905-17 - PubMed
  21. Nature. 2006 Dec 14;444(7121):881-7 - PubMed
  22. Cell Host Microbe. 2012 Nov 15;12(5):611-22 - PubMed
  23. Cell Host Microbe. 2012 Sep 13;12(3):277-88 - PubMed
  24. PLoS One. 2012;7(10):e46837 - PubMed
  25. Sci Rep. 2014 Jan 27;4:3879 - PubMed
  26. Nature. 2007 Oct 18;449(7164):804-10 - PubMed
  27. Int J Obes Relat Metab Disord. 1997 Jun;21 Suppl 3:S12-23 - PubMed
  28. Nat Rev Endocrinol. 2011 Aug 09;7(11):639-46 - PubMed
  29. Expert Rev Cardiovasc Ther. 2011 Mar;9(3):265-77 - PubMed
  30. Am J Clin Nutr. 1992 Jan;55(1 Suppl):309S-313S - PubMed
  31. J Intern Med. 2010 Oct;268(4):320-8 - PubMed
  32. Endocr Rev. 2006 Dec;27(7):750-61 - PubMed
  33. Nat Rev Endocrinol. 2013 Aug;9(8):467-78 - PubMed
  34. Nature. 2006 Dec 21;444(7122):1022-3 - PubMed
  35. Lipids Health Dis. 2014 Feb 19;13:36 - PubMed
  36. Nat Rev Drug Discov. 2012 Sep;11(9):675-91 - PubMed
  37. Annu Rev Med. 2011;62:361-80 - PubMed
  38. Nat Rev Endocrinol. 2011 Feb;7(2):69-70 - PubMed
  39. Am J Med Sci. 2013 Apr;345(4):284-8 - PubMed
  40. Nutr Clin Pract. 2012 Apr;27(2):201-14 - PubMed
  41. Cell. 2012 Mar 16;148(6):1258-70 - PubMed
  42. Eur J Clin Nutr. 2011 Nov;65(11):1173-89 - PubMed
  43. Nat Rev Endocrinol. 2010 May;6(5):255-69 - PubMed
  44. Clin Pharmacol Ther. 2011 Jul;90(1):77-89 - PubMed
  45. Int J Obes Relat Metab Disord. 1995 Apr;19(4):221-6 - PubMed
  46. Gastroenterology. 2009 May;136(6):2003-14 - PubMed
  47. Microb Pathog. 2012 Aug;53(2):100-8 - PubMed
  48. N Engl J Med. 2012 Oct 25;367(17):1577-9 - PubMed
  49. Lancet. 2011 Apr 16;377(9774):1341-52 - PubMed
  50. Physiol Rev. 2010 Jul;90(3):859-904 - PubMed
  51. Appl Environ Microbiol. 1993 Jan;59(1):15-20 - PubMed

Publication Types